{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicbpcgwyjifmof76lmwhu6qpjvuug2t7fn6peok6n5rgose7tnp3u",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mihcf5dpo2o2"
  },
  "path": "/2026/04/01/alphamab-oncology-announces-the-phase-iii-clinical-study-of-anbenitamab-kn026-combined-with-hb1801-as-neoadjuvant-treatment-for-breast-cancer-has-met-the-primary-endpoint/",
  "publishedAt": "2026-04-01T14:44:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SUZHOU, China, April 1, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with Docetaxel for Injection (Albumin-bound) (HB1801), has met […]",
  "title": "Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint"
}